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ABSTRACT
Exposure to exercise following a breast cancer diagnosis is associated with 
reductions in the risk of recurrence. However, it is not known whether breast cancers 
within the same molecular-intrinsic subtype respond differently to exercise. Syngeneic 
mouse models of claudin-low breast cancer (i.e., EO771, 4TO7, and C3(1)SV40Tag-
p16-luc) were allocated to a uniform endurance exercise treatment dose (forced 
treadmill exercise) or sham-exercise (stationary treadmill). Compared to sham-
controls, endurance exercise treatment differentially affected tumor growth rate: 
1- slowed (EO771), 2- accelerated (C3(1)SV40Tag-p16-luc), or 3- was not affected 
(4TO7). Differential sensitivity of the three tumor lines to exercise was paralleled 
by effects on intratumoral Ki-67, Hif1-α, and metabolic programming. Inhibition of 
Hif1-α synthesis by the cardiac glycoside, digoxin, completely abrogated exercise-
accelerated tumor growth in C3(1)SV40Tag-p16-luc. These results suggest that 
intratumoral Hif1-α expression is an important determinant of claudin-low breast 
cancer adaptation to exercise treatment.
INTRODUCTION
Exposure to regular exercise after a diagnosis of 
primary breast cancer may lower the risk of recurrence 
and breast cancer death, compared with low exposure 
(inactivity) [1-3]. Intriguingly, recent epidemiological 
findings indicate that breast tumor sensitivity to exercise 
may differ as a function of clinical subtype with estrogen-
receptor (ER) positive breast cancer being preferentially 
sensitive [4-6], although two independent cohort studies 
found triple negative tumors also to be responsive. [7, 8] 
Similar heterogeneity in response to exercise is observed 
in preclinical studies demonstrating that exercise inhibits 
primary breast tumor growth in some, but not all; both as a 
single modality [9, 10] and in combination with anticancer 
therapy [9, 11]. The underlying mechanisms that drive 
variation in exercise response in breast tumors are not 
currently defined.
To investigate whether breast tumors from the 
same molecular subtype exhibit a differential sensitivity 
to exercise treatment, we allocated three syngeneic 
mouse models of claudin-low breast cancer to a uniform 
endurance exercise-training dose. We show marked 
differential sensitivity of breast cancer to exercise 
treatment, which occurred with parallel changes to Hif1-α 
protein, and metabolism. Inhibition of Hif1-α synthesis 
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abrogates growth stimulatory effects of exercise in one of 
the three tumor models. These results suggest that tumors 
adapt to exercise in different ways, and that part of this 
adaptation is Hif1 mediated. 
RESULTS
Differential response of claudin-low breast cancer 
to exercise
To investigate whether breast tumors from the 
same molecular subtype exhibit a differential sensitivity 
to exercise treatment, female FVB/NJ, C57Bl/6J, and 
BALB/c mice (8-10 weeks of age) were randomized to 
endurance exercise training (treadmill running) or sham-
control (stationary treadmill) groups. Mice randomized 
to exercise were acclimatized to treadmill running for 
5.d for 10-15 mins/session at 10 m/min, followed by 
orthotopic implantation with EO771, 4TO7, or C3(1)
SV40Tag-p16-luc (mammary fat pad; 1x105 - 5x104 
-cells). Gene expression analysis showed that EO771, 
4TO7 and C3(1)SV40Tag-p16-luc clustered to a 
classification of claudin-low (Supplementary Figure 1A, 
1B). Following implantation endurance exercise was 
progressively increased to 20 m/min at 5% grade for 45 
mins, 5 d.wk for 15 days; Mice randomized to sham-
control groups were placed on a stationary treadmill for 
the same exposure time and frequency to standardize the 
environmental conditions. Body weights were not different 
across experimental groups for the duration of the study 
Figure 1: Aerobic training effects on breast tumor growth in mouse models of claudin-low breast cancer. A. Aerobic 
training effects on tumor growth over time. (Left) EO771 mouse tumor model, individual mouse tumors. Values are log (tumor volume 
mm3) over time; (n = 12/group). (Middle) 4TO7 mouse tumor model, individual mouse tumors. Values are log (tumor volume mm3) over 
time; (n = 10-12/group). (Right) C3(1)SV40Tag-p16-luc mouse tumor model, individual mouse tumors. Values are log (tumor volume 
mm3) over time; (n = 10-12/group). B. Box-plots of final tumor volumes by group. (Left) EO771. Final volumes of mouse tumors at 18-days 
post tumor cell implantation by group; **p < 0.001; p = 1x10-7. (Middle) 4TO7. Final volumes of mouse tumors at 18-days post tumor cell 
implantation by group; p = 0.23. (Right) C3(1)SV40Tag-p16-luc. Final volumes of mouse tumors at 18-days post tumor cell implantation 
by group; *p < 0.05; p = 0.03.
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(Supplementary Figure 2A). 
At day 15, tumor volumes in exercise treatment 
groups were 0.5-fold smaller and 2-fold larger in EO771 
(p < 0.001) and C3(1)SV40Tag-p16-luc (p = 0.03) tumors, 
respectively, compared with the control (Figure 1A, 1B; 
Supplementary Figure 2B; Supplementary Tables 1, 2). 
Tumor volumes at Day 15 were comparable between 
experimental groups in mice bearing 4TO7 tumors (p = 
0.23). To ensure that differences in exercise treatment dose 
delivery between tumor models were not responsible for 
the observed differential tumor sensitivity to exercise, we 
measured citrate synthase (in the quadriceps femoris), an 
established marker of oxidative capacity and physiological 
adaptation to exercise [12]. Citrate synthase activity was 
not different across the groups (Supplementary Figure 2C), 
confirming exercise treatment dose was uniform. 
To determine whether differential tumor sensitivity 
to exercise correlated with changes in proliferation or 
apoptosis, we assessed Ki-67 and Cleaved Caspase-3, 
respectively, on Day 15. Compared to controls, the number 
of Ki-67-positive cells was 0.25-fold lower in EO771 (p 
< 0.001) and 1.26-fold higher in C3(1)SV40Tag-p16-
luc (p = 0.001) in tumors of exercising animals (Figure 
2A, Supplementary Figure 3). Ki-67 positive cells were 
comparable between groups in 4T07 (p = 0.28). No 
differences in Cleaved Caspase-3 positive cells were 
observed (Figure 2B, Supplementary Figure 4). Overall, 
these findings indicate differential sensitivity to exercise in 
breast tumors within the same molecular-intrinsic subtype 
is related to differences in proliferation. 
Hif1-α protein expression is a key regulator of 
exercise sensitivity
Hypoxia-inducible factor-1 (Hif1) is a key 
transcriptional regulator of aerobic and anaerobic 
metabolism [13]. We hypothesized that Hif1 plays a 
central role in controlling growth of tumors in response 
to exercise. In the C3(1)SV40Tag-p16-luc tumor Hif1 
mediated alterations in tumor metabolism may provide 
an increase in macromolecular precursors for cell 
proliferation  [14]. On the other hand, growth inhibitory 
effects of exercise on the E0771 tumor may be related 
to downregulation of Hif1 transcriptional activity. Hif1 
activity is regulated by the oxygen sensitive sub-unit, 
Hif1-α. Under aerobic conditions, where Hif1 is inactive, 
Hif1-α is prolyl-hyroxylated and targeted for proteosomal 
degradation by the VHL complex. In normoxia, the 
relative lack of Hif1-α prevents heterodimerization and 
transcriptional activity [15] Hif1-α protein expression 
was 5-fold lower and 11-fold higher in EO771 and C3(1)
SV40Tag-p16-luc, respectively, in tumors of exercising 
mice, compared with controls (Figure 2C). There were 
no differences in Hif1-α transcript levels between control 
and exercise treatment groups, indicating that the observed 
differences in Hif1-α protein level were not driven by 
differences in rate of synthesis. (Supplementary Figure 
5B). This is to be expected, since the major point of 
regulation of Hif1-α is post-translational [15].
To investigate the importance of Hif1-α in exercise-
induced growth acceleration of C3(1)SV40Tag-p16-luc 
tumors, we used the cardiac glycoside, digoxin, to inhibit 
synthesis of Hif1-α protein [16, 17]. C3(1)SV40Tag-p16-
luc bearing animals were randomly allocated to exercise or 
digoxin monotherapy (2 mg/kg) or combination therapy. 
Compared to sham-treated animals, intratumoral Hif1-α 
protein levels were lower in the combination treatment 
group (Figure 3A) and tumor sizes were not significantly 
different. These results showed that pharmacologic 
reduction of Hif1-α protein levels completely abrogated 
exercise-induced growth acceleration of C3(1)SV40Tag-
p16-luc (Figure 3B; Supplementary Table 3). 
Exercise-induced changes in Hif1-α protein 
expression alters tumor metabolism
Hif1 targets regulate glycolytic and reductive 
glutamine activity [18]. The Hif1 gene target, pyruvate 
dehydrogenase kinase-1 (PDK-1), inhibits pyruvate 
dehydrogenase (PDH), a potent regulator of mitochondrial 
oxidation of pyruvate [19]. Activation of PDK-1 increases 
glycolysis and reduces oxidative phosphorylation (OX 
PHOS) [20]. Therefore, we hypothesized that exercise 
would increase PDK-1 levels compared with controls 
in C3(1)SV40Tag-p16-luc. Compared to sham controls, 
exercise led to 17-fold higher expression of PDK-1 in 
C3(1)SV40Tag-p16-luc, with no differences in EO771 
(Figure 4A). Similarly, expression of Glut-1 was 4.9-fold 
higher in C3(1)SV40Tag-p16-luc tumors after exercise 
treatment with no differences in EO771 (Figure 4B). These 
data suggest that differential Hif1-α protein expression led 
to Hif1-mediated changes in downstream protein targets 
involved in regulation of OX PHOS and glycolysis.
We hypothesized that the differential sensitivity 
of intratumoral Hif1-α to exercise would be linked to 
alterations in tumor metabolism. We first assessed citrate 
synthase activity in tumors, as a marker of mitochondrial 
function and OX PHOS [21]. Citrate synthase expression 
was 1.2-fold lower (p = 0.01) and 4.7-fold higher 
in EO771 and C3(1)SV40Tag-p16-luc (p = 0.01), 
respectively in tumors of exercise treated mice, compared 
with controls (Figure 4C). These results suggested there 
are inherent differences in mitochondrial activity between 
these cell lines in response to exercise. Bioenergetic 
profiling revealed a higher basal (resting) extracellular 
acidification rate (ECAR) in C3(1)SV40Tag-p16-luc 
compared to EO771 tumor cells (p = 0.04) (Supplementary 
Figure 5C). Subsequent metabolomic analysis of pathway-
associated metabolite sets showed that phenylacetate 
metabolism and the glycerol phosphate shuttle were lower 
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Figure 2: Aerobic training effects on proliferation, apoptosis, and Hif1-α in mouse breast tumors. A. Effects of aerobic 
training on tumor cell proliferation compared to control by Ki-67 index. (Left) Proliferation of tumor cells in EO771 tumors, (Middle) 
Proliferation of tumor cells in 4TO7 tumors, (Right) Proliferation of tumor cells in C3(1)Tag-p16-luc tumors. Values are mean ± S.E.M. (n 
= 10-13/group); *p < 0.05. B. Effects of aerobic training on tumor cell apoptosis compared to control. (Left) Apoptosis of tumor cells within 
EO771 tumors, (Middle) Apoptosis of tumor cells within 4TO7 tumors, (Right) Apoptosis of tumor cells within C3(1)Tag-p16-luc tumors. 
Values are mean ± S.E.M. (n = 10-13/group). C. Western blot of Hif1-α in mouse tumors: Hif1-α western blot in C3(1)SV40Tag-p16-luc 
tumors (Bottom Left), EO771 tumors (Bottom Right) C3(1)SV40Tag-p16-luc mouse tumors: Mean densitometry normalized to β-actin : 
Aerobic Training, 17.11; Control, 1.45; (p = 0.06), EO771 mouse tumors: Mean densitometry normalized to β-actin : Aerobic Training, 
6.02; Control, 1.19; (p = 0.04).
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Figure 3: Aerobic training and Hif1-α inhibitor effects on mouse breast tumor growth. A. Western blot of Hif1-α in mouse 
tumors treated with Digoxin (+) or Saline (-). Hif1-α western blot in C3(1)SV40Tag-p16-luc mouse tumors: Mean densitometry normalized 
to β-actin: Control plus Digoxin(+) 1.87; Control plus saline (-) 4.50; Aerobic Training plus saline (-) 6.87; Aerobic Training plus Digoxin 
(+) 2.58; p = 0.01 for Aerobic Training group with Digoxin compared to Aerobic Training plus saline, all other groups compared p > 0.05. 
B. C3(1)SV40Tag-p16-luc aerobic training tumor study ± Digoxin. Tumor bearing mice were treated 5 days/wk. with aerobic training 
or control ± Digoxin (2mg/kg) or equivalent volume saline based upon total bodyweight. Values are log (tumor volume) (n = 6/group); 
ANOVA analysis in table (Right). 
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in E0771 tumors after exercise treatment (Figure 5A, 
Supplementary Figure 6A) compared to control. These 
findings may partially explain exercise -induced inhibition 
of EO771 proliferation since glycerol-3-phosphate, and its 
corresponding acyltransferase, are positively correlated 
with proliferation in claudin-low breast cancer [22, 23]. 
Although the mechanisms remain to be fully elucidated, 
phenylacetate inhibits growth of several cancer cell lines 
[24]. Metabolic pathway impact analysis showed fatty 
acid, amino acid, and nucleotide metabolism were most 
affected in EO771 tumors from exercise treatment mice 
compared to control (Figure 5B). 
The biosynthesis of amino acids, lipids, and 
nucleotides from substrates in the citric acid cycle are 
an important determinant of cell proliferation [25]. In 
C3(1)SV40Tag-p16-luc, metabolite sets of the citric 
acid cycle as well as the oxidation of long chain fatty 
acids (p < 0.05) were higher after exercise treatment, 
compared to sham-controls (Figure 5C, Supplementary 
Figure 6B, Supplementary Figure 7). ATP citrate lyase 
converts glucose derived acetyl-CoA to citrate that is 
essential for lipid synthesis; the source of acetyl-CoA 
is a HIF dependent process [18]. Metabolic pathway 
impact analysis indicated that exercise also affected fatty 
acid, amino acid, and nucleotide metabolism, but in the 
opposite direction from that seen with C3(1)SV40Tag-
p16-luc (Figure 5D). Additionally, exercise led to higher 
levels of nucleotide metabolites in C3(1)SV40Tag-p16-luc 
(p < 0.05) (Figure 6). The presence of higher nucleotide 
metabolites is consistent with higher cell proliferation 
observed in C3(1)SV40Tag-p16-luc tumors of exercised 
mice [26]. 
Overall, our data suggest that exercise-induced 
differential modulation of Hif1-α and subsequent Hif1 
Figure 4: Aerobic training effects on PDK-1 gene expression, Glut-1 protein expression, and citrate synthase activity 
in mouse breast tumors. A. PDK-1 gene expression in mouse tumors. PDK-1 gene expression shown as fold change relative to control. 
(Left) C3(1)SV40Tag-p16-luc on left; (Right) EO771. (n = 6/group). Values are mean ± S.E.M.; *p < 0.05. B. Glut-1western blot. C3(1)
SV40Tag-p16-luc tumors (Left), EO771 tumors (Right); C3(1)SV40Tag-p16-luc mouse tumors: Mean densitometry normalized to β-actin : 
Aerobic Training, 8.92; Control, 1.84; (p = 0.05); EO771 mouse tumors: Mean densitometry normalized to β-actin : Aerobic Training, 8.97; 
Control, 9.91; (p = 0.61). C. Citrate synthase activity in mouse tumors. (Left) C3(1)SV40Tag-p16-luc control and aerobic training tumors, 
(Right) EO771 control and aerobic training tumors. Values are mean ± S.E.M. (n = 6/group); *p < 0.05.
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Figure 5: Metabolomic analysis of aerobic training effects on mouse breast tumors. A. Hierarchical clustering heat map of 
top 20 metabolites in aerobic training group and control tumors in EO771 mouse model. B. Pathway impact analysis in EO771 mouse 
model in aerobic training group tumors compared to control. C. Hierarchical clustering heat map of top 20 metabolites in aerobic training 
group and control tumors in C3(1)SV40Tag-p16-luc mouse model. D. Pathway impact analysis in C3(1)SV40Tag-p16-luc mouse model in 
aerobic training group tumors compared to control.
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Figure 6: Aerobic training effects on intratumoral nucleotide metabolites. Nucleotide metabolites in mouse tumors (Left) 
C3(1)SV40Tag-p16-luc; (Right) EO771. Relative abundance normalized to control; values are mean + S.E.M.; *p = 0.05-0.1, **p < 0.05.
Figure 7: Model summarizing aerobic training effects on breast tumor biological pathways in the C3(1)SV40Tag-p16-
luc model. A. Aerobic training effects on breast tumor biological pathways in the C3(1)SV40Tag-p16-luc mouse model. Aerobic training 
in mice leads to stabilization of Hif1-α protein in C3(1)SV40Tag-p16-luc tumors. Hif1-α mediates inhibition of oxidative phosphorylation 
and citric acid cycle (TCA) through PDK-1 as well as upregulation of glycolysis through Glut-1. Hif1-α also increases fatty acid oxidation 
(FAO). Together increases in Glut-1 and FAO provide precursors for tumor cell proliferation. B. Aerobic training effects on breast tumor 
biological pathways with Hif1-α inhibition in the C3(1)SV40Tag-p16-luc mouse model. Hif1-α inhibition by the cardiac glycoside Digoxin 
prevents upregulation of glycolysis and inhibition of oxidative phosphorylation and TCA. Preventing Hif1-α metabolic reprogramming 
leads to reduced metabolic dysregulation and tumor growth. C. Model summarizing aerobic training effects on breast tumor biology 
in EO771 model. Aerobic training in mice decreases Hif1-α in EO771 tumors. Decreased Hif1-α protein alters metabolism in glycerol 
phosphate and phenylacetate, which may lead to decreased breast cancer cell proliferation through lower precursor formation.
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transcriptional activity on tumor metabolism and cell 
proliferation, may underpin differential tumor sensitivity 
to exercise in claudin-low breast cancer. 
DISCUSSION
On the basis of observational studies, there is a 
growing consensus that exposure to exercise after a 
breast cancer diagnosis is associated with significant 
improvements in disease outcomes. However, there is 
a lack of consistency among risk reductions and breast 
subtypes [4-8]. Thus, identification of factors to predict 
or modulate tumor response to exercise is important, 
particularly given existence of exercise recommendations 
for cancer patients from several agencies [27, 28]. Here we 
find that modulation of Hif1-α expression plays a role in 
claudin-low breast cancer adaptation to exercise. 
In the C3(1)SV40Tag-p16-luc model, higher 
Hif1-α protein expression in tumors from exercised mice, 
contributed to acceleration of tumor growth (Figure 7). 
The importance of Hif1 in the adaptation to exercise 
was verified by inhibiting Hif1-α synthesis. Inhibition of 
Hif-1-α synthesis completely abrogated the accelerated 
growth associated with exercise. Metabolomic analysis 
in C3(1)SV40Tag-p16-luc was consistent with exercise-
mediated expression of the Hif1 target, PDK-1. Higher 
PDK-1 expression was associated with increased Glut-1, 
reductive glutamine metabolism, and fatty acid synthesis. 
PDK-1 may be an important therapeutic target in claudin-
low breast cancer to prevent metabolic reprogramming 
and inhibit accelerated tumor growth associated with 
exercise. Future studies evaluating exercise effects on 
other intratumoral Hif1 gene targets is warranted.
Interestingly, the exercise-induced acceleration 
of C3(1)SV40Tag-p16-luc is similar to prior work in 
p53 deficient MMTV-Wnt-1 [29]. Despite differences 
in tumorigenesis mechanism (transgenic p53+/-MMTV-
Wnt-1; orthotopic C3(1)SV40Tag-p16-luc), both models 
suggest that exercise “stress” may drive adaptation to an 
aggressive phenotype. While the underlying mechanisms 
in p53+/-MMTV-Wnt-1 are unknown, exercise effects on 
p53 regulation of metabolism may have enhanced tumor 
growth [30]. p53, like Hif1, is a key mediator of cellular 
respiratory and glycolytic pathways. Since cross-talk 
exists between p53 and Hif1 [31], it is plausible that a 
metabolic shift towards increased glycolysis or reductive 
glutamine metabolism may be a common underlying 
mechanism for augmented tumor growth with exercise in 
the p53+/-MMTV-Wnt-1 and the C3(1)SV40Tag-p16-luc. 
In contrast to C3(1)SV40Tag-p16-luc, exercise 
inhibited tumor growth in the EO771 model [9]. Here, 
exercise reduced Hif1-α levels and slowed tumor cell 
proliferation and tumor growth. Metabolomic data were 
diametrically opposed to that seen with C3(1)SV40Tag-
p16-luc, indicating that this tumor was not able to adapt to 
exercise to support cellular proliferation and survival. The 
differences in responsiveness of C3(1)SV40Tag-p16-luc 
and E0771 to exercise may lie in their inherent differences 
in baseline metabolism. The C3(1)SV40Tag-p16-luc had 
a more glycolytic phenotype at baseline and may be able 
to more readily adapt to conditions of exercise than the 
E0771 tumor line.
The 4TO7 mouse model did not display tumor 
sensitivity to exercise. Tumor proliferation was 
comparable between groups suggesting that tumor growth 
in 4TO7 does not depend on Hif1. However, it is possible 
that our exercise prescription was insufficient to alter 
Hif1-α protein. Further interrogation into various exercise 
prescriptions and modalities in 4TO7 may help identify 
intratumoral targets that improve exercise sensitivity.
One limitation of our study is that we utilized 
citrate synthase activity as a surrogate measurement 
for the citric acid cycle and oxidative phosphorylation 
in tumors. Direct measurements of electron transport 
chain complexes provide a more accurate assessment of 
changes in oxidative phosphorylation. However, citrate 
synthase activity is commonly utilized to normalize 
oxidative phosphorylation enzymatic activities in 
isolated mitochondria, and thus may serve as an accurate 
surrogate marker [32]. Additionally, we did not directly 
measure hypoxia or perfusion in these experiments and 
can only speculate as to the role that differences in these 
physiologic parameters would have had on tumor growth 
and the Hif1-α signaling pathway. 
Targeting breast cancer cellular metabolism may 
have clinical promise since actionable targets to treat 
triple-negative breast cancer, especially the claudin-low 
molecular intrinsic subtype, are lacking [33]. Many studies 
are investigating the uses of targeted inhibitors of key 
metabolic pathways to reverse metabolic dysregulation of 
breast tumors [34]. Our results suggest that exercise may 
be one effective strategy to alter claudin-low breast cancer 
metabolism. Furthermore, we demonstrate that exercise 
can modulate major cancer-intrinsic signaling pathways 
resulting in marked divergent growth promoting or 
inhibitory phenotypes. These data, by definition, challenge 
the longstanding rhetoric that exercise is a generic therapy 
that “works for everything” to one in which requires the 
adoption of a personalized medicine approach to fully 
interrogate the molecular mechanisms and predictors of 
response to optimize safety and efficacy.
MATERIALS AND METHODS
Cell culture
C3(1)SV40Tag-p16-luc breast cancer cells that 
stably express luciferase were kindly provided by the lab 
of Dr. Ned Sharpless and the UNC Mouse Phase 1 Unit, 
University of North Carolina. C3(1)SV40Tag-p16-luc 
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cells were isolated from the tumor of a C3(1)SV40Tag 
transgenic mouse and transfected with a stable expressing 
p16 luciferase reporter. C3(1)SV40Tag-p16-luc cells were 
cultured in DMEM (High glucose, CellGro) supplemented 
with 10% fetal bovine serum, antibiotic-antimycotic (Life 
technologies), and 0.2mg/kg G418/Geneticin. EO771 
breast cancer cells were cultured in RPMI-1640 with 
L-glutamine, 8% fetal bovine serum, sodium pyruvate 
(Life Technologies), and MEM non-essential amino acids 
(Life technologies). 4TO7 cells were grown in DMEM 
supplemented with 10% fetal bovine serum and antibiotic-
antimycotic (Life Technologies). All cells were trypsinized 
at 80% confluence in log phase growth. 
Mouse cell line breast cancer molecular subtyping
C3(1)SV40Tag-p16-luc, EO771, and 4TO7 cell 
lines were subjected to micro-array and cluster analysis 
by the University of North Carolina Mouse Phase I Unit 
to determine specific breast cancer subtype; all cells lines 
clustered with the claudin-low breast cancer subtype 
(data not shown). Microarray analysis was performed as 
previously described [35]. Briefly, total RNA was purified 
from 20-30 mg of mouse mammary tumor using a Qiagen 
(Valencia, CA USA) RNeasy Mini Kit following the 
manufacture’s protocols. RNA quantity was determined 
using a Nanodrop spectrophotometer. An Agilent Low 
RNA Input Fluorescent Linear Amplification Kit was 
used and total tumor RNA was reverse transcribed and 
labeled with cyanine-5 (Cy5) dye for experimental 
samples. Whole mouse total RNA was labeled with 
cyanine-3 (Cy3) dye and used for the reference samples. 
Equal quantities of the labeled mouse reference RNA 
and tumor RNA were hybridized overnight to Agilent 
4X180K microarrays. They were then washed, scanned, 
and their signal intensities were determined. Microarray 
data was stored in and extracted from the UNC Microarray 
Database as log2 Cy5/Cy3 ratios. The values for each 
probe were Lowess normalized and those with intensity 
values greater than 10 in both channels were selected 
then the median expression value was calculated for each 
probe. Hierarchical clustering was performed with the 
unsupervised data set using centroid linkage and was then 
viewed using Java Treeview [36].
Mice
7-9 week old female mice (FVB/NJ, BALB/c, C57/
Bl6) were obtained from Jackson Labs and maintained 
on a reverse 12:12 hour light-dark cycle in a low-stress 
environment. Animals were group housed ~4-5 mice/cage 
and provided food and water ad libitum. Animal care and 
all experimental procedures were in accordance with the 
Institutional Animal Care and Use Guidelines at Duke 
University Medical Center.
Orthotopic tumor cell implantation
Cell lines were trypsinized at 80% confluence and 
resuspended 1:1 in Hank’s Balanced Salt Solution (HBSS) 
(Life technologies) or Phosphate-Buffered Saline (PBS) 
(Life technologies) in matrigel (BD Biosciences). Phenol-
red free matrigel was used for EO771 cells as data by 
our own group suggest they are estrogen receptor (ER) 
responsive (data not shown). Mice were anesthetized using 
intraperitoneal injections of ketamine (8.5 mg/kg) and 
xylazine (8.5 mg/kg). Prior to tumor cells implantation, 
mouse hair was removed around area of injection site 
with Nair™ (Church & Dwight Co., Inc., Ewing, NJ) to 
allow for improved accuracy of surgical implantation of 
tumor cells and enhanced tumor volume measurements. 
Following hair removal, the surgical field was prepared 
using three alternating applications of chlorohexidine 
gluconate scrub solution and 70% ethanol. Using a sterile 
scalpel, a skin incision was made exposing the dorsal 
mammary fat pad and 5 x 104 C3(1)SV40Tag-p16-luc 
cells were injected in 0.1ml of 1:1 HBSS and Phenol-
red containing matrigel per FVB/NJ female mouse; 1 x 
105 EO771 cells were injected in 0.1ml of 1:1 PBS and 
Phenol-red free matrigel per C57/Bl6 female mouse; 
2.5 x 105 4TO7 cells were injected in 0.1ml of 1:1 PBS 
and Phenol-red containing matrigel per BALB/c female 
mouse. The number of cells injected was determined in a 
prior pilot study to obtain the minimum number of cells 
to form breast tumors and allow for consistent number of 
days of aerobic training. 
Aerobic training intervention
Mice were assigned to either aerobic training (n 
= 12) or control (n = 12) treatment. Control mice were 
placed on stationary treadmills (Columbus Instruments, 
Columbus, OH) in the same room as the aerobic training 
group during training sessions to maintain identical 
environmental conditions for all mice. Stationary 
treadmills were powered on, but the treadmill belt 
remained idle during the intervention. Aerobic training 
sessions were performed at the beginning of the active dark 
cycle in order to more accurately assess normal murine 
physiologic tendencies towards physical activity. The 
aerobic training group participated in an acclimatization 
period prior to study initiation. The acclimatization period 
on the treadmill (Columbus Instruments, Columbus, OH) 
apparatus consisted of the following: 5 minutes at 5m/
min. at 5% grade on pre-study Day 1; pre-study Days 2-4 
speed was increased by 5m/min. each day for 5 additional 
minutes until a final dose was achieved of 20m/min. for 5 
minutes on pre-study Day 4. Pre-study Day 5, control and 
aerobic training groups of mice were injected with breast 
cancer cell lines; this date was considered study Day 1. 
On study Day 3, the aerobic training intervention was 
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initiated. Mice in the aerobic training group were treated 5 
consecutive days/wk. using the following aerobic training 
doses: 5m/min for 5min., 10m/min. for 5min., 15m/min. 
for 5 min., and 20m/min. for 45 min., which is equivalent 
to 70% VO2peak as previously described [37]. Total aerobic 
training time per session was 60 minutes with an average 
overall distance completed of 1,055m.
Digoxin and saline treatment in mice
Following aerobic training using the protocol 
previously described or control (placement of mice on a 
stationary treadmills), mice were injected intraperitoneally 
(i.p.) with either digoxin at 2mg/kg or equivalent volume 
of saline for corresponding bodyweight using 1ml 
syringes. Digoxin was purchased from Duke University 
Hospital Pharmacy as 250 mcg/1ml ampules. Mice (n = 6/
group) were injected 5 days/week immediately following 
the exercise prescription or control.
Breast tumor measurement and body weight
Mouse tumors and body weights were measured 
three times per week using digital calipers and a digital 
scale respectively. Length and width measurements in 
millimeters (mm) were recorded and tumor volume was 
calculated using ((l x w2)/2). 
Sacrifice and tissue collection
All animals were sacrificed at ~18 days post breast 
cancer cell line injection and 24 hr. following the last 
aerobic training session using an intraperitoneal (i.p.) 
injection of 0.05ml Euthasol®. Tumors were surgically 
removed and measured using calipers to determine 
final tumor volume. Additionally, tumors were weighed 
to investigate differences in tumor mass and hearts 
were weighed to examine cardiomyopathy as a result 
of physiologic adaptation to aerobic training. Muscle 
was excised from the quadricep femoris to investigate 
muscle adaptations to aerobic training stimulus. Tumor 
and muscle tissue were flash frozen in liquid nitrogen 
and stored at -80°C until analysis. A portion (~40%) of 
tumor tissue was fixed in formalin and stored at 4°C in 
70% ETOH. 
Citrate synthase activity
-80°C stored frozen mouse quadricep femoris 
and tumor tissue (~25mg) were homogenized at 4°C 
with a motorized tissue homogenizer for ~3s cycles in 
MT Cell Lysis Solution (Sigma-Aldrich) supplemented 
with protease inhibitor cocktail solution at 1:10 dilution 
(Roche) and 1x phosphatase inhibitor cocktail solution 
(Sigma-Aldrich). Homogenized tissue solution was then 
spun at 14,000 rpm at 4°C for 10 min. and supernatant 
was collected. BCA protein assay (Thermo Scientific) was 
then performed according to the manufacturer protocol, 
and protein concentration was determined against BSA 
standards from an absorption wavelength of 550nm on a 
BioRad 680 Plate Reader. 8μg of total protein lysate per 
sample was used in accordance with the Citrate Synthase 
Assay Kit (Sigma-Aldrich). Samples were run in triplicate 
on a 96-well microplate. Maximal velocity measurements 
were recorded at 415nm in 10-second intervals for 90 
seconds. Net citrate synthase activity was determined 
from the equation provided in the Sigma Aldrich Citrate 
Synthase Assay protocol manual. 
Seahorse bioenergetic analysis
The XF24 Analyzer (Seahorse Biosciences, North 
Billerica MA) was used to measure the bioenergetic 
profile of C3(1)SV40Tag-p16-luc and E0771 cell lines. 
The XF24 analyzer allows for real-time measurements 
of extracellular acidification rate (ECAR). Mitochondrial 
function was determined in the presence of mitochondrial 
uncoupling drugs Oligomycin, FCCP and antimycin. A; 
these were injected sequentially through ports in the XF 
Assay cartridges to final concentrations of 1 μg/ml, 1 μM 
and 10 μM respectively. This allowed for the determination 
of baseline mitochondrial activity, energy consumption 
from ATP production, and maximal respiration.
Cells are plated into the XF24 cell culture plate 
(Agilent Technologies) at a density of 60,000 cells per 
well, 5 wells per cell line. This is a density previously 
determined to produce a confluent plate the following 
morning. Cells were incubated overnight in regular growth 
medium to allow for attachment. 1 hour prior to assay 
initiation, the growth media was removed for DMEM 
(Agilent Technologies) supplemented with 0.18% glucose 
(45% D-(+)-glucose, Sigma), sodium pyruvate (Thermo), 
and glutamax (Thermo). At run completion, BCA assay 
provided total protein per well per cell line, confirming 
that variation in cell density was not a contributing factor 
to the observed effects. Data was averaged for each cell 
line. Statistical analysis was performed via 2-way ANOVA 
using the Graphpad PRISM software. 
RT-PCR
RNA was extracted from frozen ~25 mg sections of 
tumors using the Qiagen RNeasy Miniprep Kit (Qiagen, 
Inc, Valencia, CA) according to the manufacturer’s 
protocol. One μg of RNA was reverse-transcribed using 
the Bio-Rad iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Inc, Hercules, CA), and resulting cDNA was 
stored at -20°C until analysis. Quantitative Real-Time PCR 
(QPCR) was performed using SsoAdvanced Universal 
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SYBRGreen Supermix (Bio-Rad) on a Roche LightCycler 
480 (Roche): Polymerase Activation and Denaturation, 30s 
at 95°C; 35 cycles of 10s at 95°C (Denaturation), 20s at 
60°C (Annealing/Extension); 65°C-95°C, 0.5°C increment 
2 sec/step (Melt Curve Analysis). Gene expression was 
quantified (2-ΔΔCp) relative to the β-actin housekeeping 
gene. All primers were purchased and validated from Bio-
Rad using Bio-Rad pre-selected target sequences: β-actin 
qMmuCED0027505; Hif1-α qMmuCID0005501; Pdk-1 
qMmuCED0044540.
Western blot
Protein lysates were obtained using the methods 
described in the Citrate Synthase Activity methods sub-
section. Denatured protein lysates were subjected to a 
NuPAGE Novex 4-12% Bis-Tris protein gel, transferred 
to membranes, and blocked in 5% milk/Tris-buffered 
saline with 0.1% Tween-20 (TBST) or 5% BSA/Tris-
buffered saline with 0.1% Tween-20 for one hour. After 
washing with TBST, membranes were incubated with 
primary antibodies in 5% BSA/TBST overnight at 4°C. 
Primary antibodies were used at the following dilutions: 
anti-Hif1-α (CS-3716) Cell Signaling Technology 
(Beverly, MA) 1:500, anti-phospho-p70S6Kinase (CS-
9234) Cell Signaling Technology (Beverly, MA) 1:500, 
anti-β-actin (SC-47778) Santa Cruz Biotechnology 
(Santa Cruz, CA) 1:4000, anti-phospho-Akt (CS-4060) 
Cell Signaling Technology (Beverly, MA) 1:1000, anti-
Glut-1 (ab-652) Abcam (Cambridge, MA) 1:1000. After 
washing with TBST, membranes were incubated with 
peroxidase-conjugated donkey anti-rabbit secondary 
antibody (SC-2313) Santa Cruz Biotechnology (Santa 
Cruz, CA) at 1:20,000 in 1%milk/TBST for 1.5 hours at 
room temperature. After washing with TBST, blots were 
visualized with SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific; Rockford IL) on a Kodak 
Image Station 2000mm. Densitometric analysis was 
performed using Carestream Molecular Imaging software 
v. 5.0.2.30 (Carestream Health, Inc.).
IHC
Ki67
Paraffin embedded sections were deparaffinized and 
rehydrated through a xylene, 100% ETOH, 95% ETOH, 
dH2O gradient. Slides were then washed in dH2O and 
antigen was unmasked in boiling 10mM sodium citrate pH 
6.0 for 10 minutes. Slides were incubated in 3% hydrogen 
peroxide and each slide was blocked in 5% Goat Serum/
TBST for one hour. Primary Ki-67 antibody (CS-12202) 
Cell Signaling Technology (Beverly, MA) was diluted 
1:400 in SignalStain Antibody Diluent Cell Signaling 
Technology (Beverly, MA) and incubated overnight at 
4°C. Slides were washed with TBST and covered with 
three drops of SignalStain Boost Detection Reagent (CS-
8114) Cell Signaling Technology (Beverly, MA). After 
washing with TBST slides were stained with SignalStain 
DAB Substrate kit (CS-8059) Cell Signaling Technolgy 
(Beverly, MA), counterstained with hematoxylin, 
dehydrated, and coverslipped.
Cleaved caspase-3
Paraffin embedded sections were deparaffinized 
and rehydrated through a xylene, 100% ETOH, 95% 
ETOH, dH2O gradient. Slides were then washed in dH2O 
and antigen was unmasked in boiling 10mM sodium 
citrate pH 6.0 for 10 minutes. Slides were incubated in 
3% hydrogen peroxide and each slide was blocked in 
5% Goat Serum/TBST for one hour. Primary Cleaved 
Caspase-3 antibody (CS-9579) Cell Signaling Technology 
(Beverly, MA) was diluted 1:500 in SignalStain Antibody 
Diluent Cell Signaling Technology (Beverly, MA) and 
incubated overnight at 4°C. As a negative control Rabbit 
isotype (CS-3900) Cell Signaling Technology (Beverly, 
MA) was used at 1:500 dilution. Slides were washed with 
TBST and covered with three drops of SignalStain Boost 
Detection Reagent (CS-8114) Cell Signaling Technology 
(Beverly, MA). After washing with TBST slides were 
stained with SignalStain DAB Substrate kit (CS-8059) 
Cell Signaling Technolgy (Beverly, MA), counterstained 
with hematoxylin, dehydrated, and coverslipped.
Microscopy and image analysis
Briefly, Ki67 and Cleaved Caspase-3 slides were 
captured on an Applied Biosystems Arcturus LCM System 
using Arcturus XT software (Life Technologies, Grand 
Island, NY). Image J software (NIH, http://imagej.nih.
gov/ij/) was used to manually count cells for Ki-67 and 
Cleaved Caspase-3.
Metabolomics
Metabolite extraction in tumor
Mouse tumors were extracted the same way as 
described previously [38]. Briefly, the tumor sample was 
first homogenized in liquid nitrogen and then 5 to 10 mg 
was weighed in a new Eppendorf tube. Ice cold extraction 
solvent (250 µl) was added to tissue sample, and a pellet 
mixer was used to further break down the tissue chunk and 
form an even suspension. After incubation on ice for an 
additional 10 min, the tissue extract was centrifuged with 
the speed of 20 000 g at 4 °C for 10 min. The supernatant 
containing 1.5 mg tissue extract was transferred to a new 
Eppendorf tube and dried in vacuum concentrator. The 
dry pellets were reconstituted into 30 µl sample solvent 
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(water:methanol:acetonitrile, 2:1:1, v/v) and further 
analyzed by LC-high resolution mass spectrometer 
(HRMS).
LC-HRMS
Ultimate 3000 UHPLC (Dionex) is coupled to 
Q Exactive Plus-Mass spectrometer (QE-MS, Thermo 
Scientific) for metabolite separation and detection. For 
polar metabolite analysis, a hydrophilic interaction 
chromatography method (HILIC) with an Xbridge 
amide column (100 x 2.1 mm i.d., 3.5 µm; Waters) is 
used for compound separation at room temperature. The 
instrument condition, mobile phase, gradient information 
and metabolomics data analysis were described previously 
except that mobile phase A was replaced with water 
containing 5 mM ammonium acetate (pH 6.8) [39].
Statistical analysis
Statistical analysis was carried out using SAS 
University Edition (SAS Institute, Inc, Cary, NC). 
Descriptive statistics are presented as mean ± SEM. One-
way ANOVA was used to compare differences in tumor 
variables between groups. Differences in apoptosis, 
proliferation, gene expression, citrate synthase activity 
and, densitometric values were evaluated using t-tests. For 
all tests, p < 0.05 was considered statistically significant.
Analysis of exercise effect on tumor growth rate
We fit a model of the form:
  (0.1)
Where yij(t) is the tumor volume at time t for the 
i-th animal in the j-th group (Control or Aerobic Exercise). 
Model (0.1)  explains variation in tumor volumes in terms 
of an initial baseline volume μ, representing the Control 
group at time 0, an effect for the aerobic exercise on the 
initial tumor volume αj, an effect for the i-th animal on 
the initial tumor volume bi, assumed to have a zero mean 
Gaussian distribution, a linear growth rate for the baseline 
group β and an effect of aerobic exercise on the growth 
rate βj. Finally εijt is measurement error, also assumed to 
have a zero mean Gaussian distribution, independent of bi. 
Model  was fit to the data using the method of restricted 
maximum likelihood using the nlme package in the R 
computing platform (www.r-project.org). 
Metabolomics analysis
Using MetaboAnalyst 3.0 (www.metaboanalyst.
ca) pathway analysis was performed using HMDB ID, 
without data filtering, normalization, transformation, or 
scaling. The parameters for the pathway impact analysis 
were pathway-associated metabolite sets in mice using 
all of the compounds in the set library. Statistical analysis 
was performed using unpaired sample concentrations, 
without data filtering, normalization, transformation, or 
scaling. Hierarchical clustering was executed using heat 
map with the following settings: detailed view, samples 
not reorganized, top 20, showing cell borders.
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